WuXi Biologics and Oxford BioTherapeutics (OBT) announced the company has selected a second bispecific program that will combine an anti-PD-L1 antibody with OBT’s immuno-oncology (IO) candidate, OX003. OBT will research and develop OX003/PD-L1, which employs WuXi Biologics’ proprietary bispecific antibody platform WuXiBody®.
“We are pleased to extend our IO partnership with WuXi Biologics, by combining a second bispecific antibody from WuXi Biologics’ proprietary bispecific platform with one of our leading clinical IO assets, OX003,” said Dr. Christian Rohlff, CEO of Oxford BioTherapeutics. “This designation represents the second advancement of our immuno-oncology partnership with WuXi Biologics, in which we will research, develop and commercialize five novel bispecific antibodies for the treatment of several cancer types. Combining the potent immune stimulatory activity of OX003 with the ability to block PD-L1 in a single agent, OX003/PD-L1 has the potential to achieve broad utility across many solid and liquid tumor types while simultaneously improving the risk/benefit ratio, reducing costs and maximizing future commercial potential. This product is the second molecule with WuXiBody® in our partnership, following the design of OX001/PD-L1, which is now entering pre-clinical development.”
“We are glad that significant progress has been made from our strategic partnership with OBT, one of the earlier adopters of our proprietary WuXiBody® platform,” said Dr. Chris Chen, CEO of WuXi Biologics. “Globally the first WuXiBody® based bispecific is in a phase I clinical trial. Broad applications of this innovative non-specific platform further validate our beliefs that this platform addresses most technical limitations of current bispecific technologies and has the potential to tremendously expedite bispecific development and reduce the cost of making these biologics. WuXi Biologics will continue to invest in developing next-generation technologies to transform biologics discovery, development and manufacturing.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!
OX003R is a unique immuno-modulatory receptor discovered by OBT to be highly expressed in tumor infiltrating lymphocytes (TILs) of ten different solid tumor types and in activated T cells. OBT has developed anti-OX003 as a humanized first-in-class antibody directed against the human extracellular domain of OX003R antigen. It shows a strong agonistic effect on activated CD8+ T cells promoting their proliferation, cytokine secretion, and cytolytic ability, and suppresses Treg function. The antitumor activity of OX003 is demonstrated by enhancement of cytotoxicity of tumor cells (including HCT116, MDA-MB-231, and BT474). OBT plans to investigate the safety, pharmacokinetics and efficacy of OX003 antibody therapy as a single agent in a Phase I clinical study in patients across a range of solid tumors, especially in human cancers that show the presence of TILs, including small cell lung cancer, non-small cell lung cancer, skin cancer, breast cancer.